Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894483 | 0.88 | TGFBR1 (0.37) | TGFBR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1897133 | 0.84 | SLC6A4 (0.43) | JAK2JAK1TYK2JAK3SRC | |
| Hydrochloric Acid SCHEMBL1897933 | 0.84 | SLC6A4 (0.45) | JAK2JAK1TYK2JAK3SRC | |
| SCHEMBL1898044 | 0.79 | TLR8 (0.42) | SRC | |
| SCHEMBL4534637 | 0.76 | JAK1 (0.40) | TGFBR1JAK1JAK3 | |
| SCHEMBL5532872 | 0.74 | TLR7 (0.39) | TGFBR1JAK1JAK3KCNH2 | |
| SCHEMBL1898506 | 0.74 | SRC (0.36) | TGFBR1SRCHTR2AHTR2C | |
| SCHEMBL1901666 | 0.72 | ADORA2A (0.41) | KCNH2 | |
| SCHEMBL1897131 | 0.72 | SLC6A4 (0.37) | JAK2JAK1TYK2JAK3SRC | |
| Hydrochloric Acid SCHEMBL1897931 | 0.71 | SLC6A4 (0.39) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | IL4, IL2, IL1A | TGFBR1 2880/4885JAK2 73/4885JAK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.